《渤健Biogen（BIIB）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（109页）.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen（BIIB）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（109页）.pdf（109页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934C

2、ommission File Number 0-19311BIOGEN INC.(Exact name of registrant as specified in its charter)Delaware 33-0112644(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)225 Binney Street,Cambridge,MA 02142(617)679-2000(Address,including zip code,and telephone n

3、umber,includingarea code,of registrants principal executive offices)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock,$0.0005 par valueBIIBThe Nasdaq Global Select MarketIndicate by check mark whether t

4、he registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to suchfiling requirements for the past 90 da

5、ys:Yes x No oIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was required to sub

6、mit suchfiles):Yes x No oIndicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company,or an emerging growth company.See the definitions of“large accelerated filer,”“accelerated filer,”“smaller reporting company,”a